While AI enables rapid drug creation for single individuals (n-of-1), the economic model is broken. It is not a commercial opportunity, creating an urgent societal challenge to develop new funding mechanisms like public-private partnerships to support these life-saving, non-scalable treatments.

AI strategies often fail to get sustained funding because they lack detailed financial models beyond simple cost savings. A credible blueprint must quantify projected revenue uplift for each initiative, a step often skipped because strategists lack the deep pharma AI experience to make accurate forecasts.

Tech-focused venture firms are finding their AI investment thesis fails in biotech. Despite massive paper profits in tech AI, their biotech AI portfolios show negative returns. This is because AI has yet to solve the complex biological bottlenecks of drug development, particularly in clinical trials, which remain slow and costly.

The transformational power of AI in life sciences isn't just designing novel molecules, which fails to solve the costly clinical development bottleneck. Instead, agentic AI provides immense leverage to individual scientists, automating tasks like protocol writing and experiment analysis that previously took weeks.

While AI for novel drug discovery has lofty goals, its most practical value lies in accelerating development. This includes applying AI to de-risked assets for new indications, improving delivery methods, and designing faster, more effective clinical trials, which is where the real bottleneck lies.

The key advantage for AI biotech isn't the model itself, but generating massive, proprietary datasets ("science tokens") via automated labs. This novel data, which doesn't exist publicly, is crucial for training superior models and achieving true scientific intelligence.

Previously, it was believed the only path to value in biotech was developing a drug. Now, AI models are proving so effective at accelerating R&D that traditional software and platform business models are becoming highly valuable and viable for serving large pharma customers.

OpenAI plans to demand revenue shares from drugs developed using its AI and a cut of e-commerce transactions. This transforms its business model from a simple per-token utility into a complex, risk-involved partner in multiple industries, akin to a venture firm.

While AI offers some time savings, A-Alpha Bio's CEO argues this is minimal in the overall drug development timeline. The transformative impact is AI's ability to engineer therapeutics with novel properties, like binding to previously inaccessible epitopes, that traditional discovery methods could never find.